Paper Details

  1. Home
  2. Paper Details

BCR-ABL inhibitors: updates in the management of patients with chronic-phase chronic myeloid leukemia.

Author: BixbyDale L, KhanAdeel M

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

The approval of second-generation BCR-ABL inhibitors, such as dasatinib and nilotinib, has expanded treatment options for patients with chronic-phase chronic myeloid leukemia. These agents are effective for both front-line treatment and for patients with resistance or intolerance to imatinib. Newer agents, like bosutinib, ponatinib, and omacetaxine, are also available for patients with resistance or intolerance to prior therapy. The selection and monitoring of therapy require careful consideration of patient-specific factors, such as comorbidities and potential side effects.
Paper Details　
Original Abstract of the Article :
OBJECTIVES: This article reviews recent clinical experiences with first-line and second-line second-generation BCR-ABL inhibitors and discusses considerations for selection of therapy for patients with chronic-phase chronic myeloid leukemia. METHODS: We reviewed recent publications on PubMed and ab...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1179/1607845413Y.0000000119

データ提供：米国国立医学図書館（NLM）

BCR-ABL Inhibitors: A New Generation of Weapons in the Fight Against Chronic Myeloid Leukemia

Chronic myeloid leukemia (CML) is a type of blood cancer characterized by the presence of the BCR-ABL fusion gene. The development of BCR-ABL inhibitors has revolutionized the treatment of CML, offering patients a chance for long-term survival. This review examines the latest advancements in BCR-ABL inhibitor therapy, focusing on second-generation inhibitors like dasatinib and nilotinib, which have proven effective in treating both newly diagnosed and resistant cases of CML. The review also discusses the emergence of newer inhibitors, including bosutinib, ponatinib, and omacetaxine, which offer hope for patients who have developed resistance to prior therapies.

A Shift in Treatment Strategies

The availability of multiple BCR-ABL inhibitors has expanded treatment options for patients with CML. The review highlights the importance of selecting the right inhibitor based on individual patient characteristics and potential side effects. It emphasizes the need for careful monitoring and adjustments in treatment plans to ensure optimal outcomes.

Navigating the Shifting Sands of CML Treatment

The landscape of CML treatment is continuously evolving, with new inhibitors and treatment strategies emerging. This review provides a valuable roadmap for navigating the complexities of this evolving field, helping healthcare providers to make informed decisions and provide the best possible care for their patients.

Dr.Camel's Conclusion

The discovery of BCR-ABL inhibitors is like finding a hidden spring in the desert. It has brought hope and a renewed sense of optimism to the fight against CML. The ongoing research and development of new inhibitors are like a persistent caravan, continuously seeking better ways to conquer this challenging disease.

Date :
  1. Date Completed 2015-01-29
  2. Date Revised 2022-01-14
Further Info :

Pubmed ID

24143950

DOI: Digital Object Identifier

10.1179/1607845413Y.0000000119

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.